Nicole Germino
Stock Analyst at Truist Securities
(4.17)
# 436
Out of 4,906 analysts
24
Total ratings
57.14%
Success rate
15.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $18 → $14 | $4.31 | +224.83% | 3 | May 14, 2025 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $8 | $4.20 | +90.48% | 3 | May 14, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $102.56 | +5.31% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.51 | +880.01% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $18.68 | +28.48% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $10.18 | - | 2 | Sep 3, 2021 |
Y-mAbs Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $4.31
Upside: +224.83%
Perspective Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.20
Upside: +90.48%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $102.56
Upside: +5.31%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.51
Upside: +880.01%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $18.68
Upside: +28.48%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.18
Upside: -